Live Breaking News & Updates on Olalekan oluwole

Stay informed with the latest breaking news from Olalekan oluwole on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Olalekan oluwole and stay connected to the pulse of your community

KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023

KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023  Stockley Park, UK – 19 April 2023 – Kite, a Gilead Company, will support eight data presentations, including updated findings in multiple indications across its portfolio of two CAR T-c...

France , Australia , Paris , France-general- , United-kingdom , Canada , Singapore , Santa-monica , California , United-states , Foster-city , Bijal-shah

Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 Congress

Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d...

Italy , Australia , United-states , Canada , Italian , David-sallman , Armin-ghobadi , Krish-patel , Patrickm-reagan , Natalia-garcia-martin , Brexucabtagene-autoleucel-brexu , Jason-westin

Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting

Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting Primary analysis of pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphomaLong-term overall survival and safety management data...

Australia , United-states , Canada , How-long , New-south-wales , Caron-jacobson , Tom-van-meerten , Dick-sundh , Fred-locke , Cressida-robson , Patrick-johnston , Axicabtagene-ciloleucel